Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
NUVA's Cash-to-Debt is ranked lower than
89% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. NUVA: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NUVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: 0.82 Max: No Debt
Current: 0.2
Equity-to-Asset 0.45
NUVA's Equity-to-Asset is ranked lower than
76% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NUVA: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
NUVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 0.93
Current: 0.45
0.36
0.93
Debt-to-Equity 0.91
NUVA's Debt-to-Equity is ranked lower than
87% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 0.27 vs. NUVA: 0.91 )
Ranked among companies with meaningful Debt-to-Equity only.
NUVA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.76 Max: 1.31
Current: 0.91
0
1.31
Debt-to-EBITDA 3.01
NUVA's Debt-to-EBITDA is ranked lower than
69% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NUVA: 3.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NUVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.59  Med: 3.46 Max: 200.35
Current: 3.01
-8.59
200.35
Interest Coverage 2.52
NUVA's Interest Coverage is ranked lower than
92% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. NUVA: 2.52 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.65  Med: 2.32 Max: No Debt
Current: 2.52
Piotroski F-Score: 5
Altman Z-Score: 2.80
Beneish M-Score: -2.39
WACC vs ROIC
8.48%
4.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 10.20
NUVA's Operating Margin % is ranked higher than
71% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. NUVA: 10.20 )
Ranked among companies with meaningful Operating Margin % only.
NUVA' s Operating Margin % Range Over the Past 10 Years
Min: -15.73  Med: 3.95 Max: 17.15
Current: 10.2
-15.73
17.15
Net Margin % 3.50
NUVA's Net Margin % is ranked higher than
58% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. NUVA: 3.50 )
Ranked among companies with meaningful Net Margin % only.
NUVA' s Net Margin % Range Over the Past 10 Years
Min: -12.92  Med: 0.83 Max: 16.37
Current: 3.5
-12.92
16.37
ROE % 5.07
NUVA's ROE % is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. NUVA: 5.07 )
Ranked among companies with meaningful ROE % only.
NUVA' s ROE % Range Over the Past 10 Years
Min: -15.05  Med: 1 Max: 21.43
Current: 5.07
-15.05
21.43
ROA % 2.24
NUVA's ROA % is ranked higher than
59% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. NUVA: 2.24 )
Ranked among companies with meaningful ROA % only.
NUVA' s ROA % Range Over the Past 10 Years
Min: -7.72  Med: 0.47 Max: 10.76
Current: 2.24
-7.72
10.76
ROC (Joel Greenblatt) % 23.23
NUVA's ROC (Joel Greenblatt) % is ranked higher than
71% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. NUVA: 23.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NUVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42.62  Med: 10.28 Max: 47.3
Current: 23.23
-42.62
47.3
3-Year Revenue Growth Rate 6.70
NUVA's 3-Year Revenue Growth Rate is ranked higher than
55% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. NUVA: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NUVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.2  Med: 12.55 Max: 480.7
Current: 6.7
-40.2
480.7
3-Year EBITDA Growth Rate 21.60
NUVA's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NUVA: 21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NUVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -36.3 Max: 24.4
Current: 21.6
0
24.4
3-Year EPS without NRI Growth Rate 59.50
NUVA's 3-Year EPS without NRI Growth Rate is ranked higher than
91% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NUVA: 59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NUVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: -30.4 Max: 162.1
Current: 59.5
-66.3
162.1
GuruFocus has detected 1 Warning Sign with NuVasive Inc $NUVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NUVA's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NUVA Guru Trades in Q3 2016

Jana Partners 80,744 sh (New)
Paul Tudor Jones 5,600 sh (+50.86%)
Pioneer Investments 70,786 sh (+11.32%)
Ken Fisher 1,422,585 sh (+0.69%)
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 869,000 sh (-0.07%)
Mario Gabelli 165,000 sh (-1.20%)
Jim Simons 129,600 sh (-59.40%)
» More
Q4 2016

NUVA Guru Trades in Q4 2016

Andreas Halvorsen 695,707 sh (New)
Jana Partners 1,810,169 sh (+2141.86%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 162,500 sh (-1.52%)
Ken Fisher 1,398,259 sh (-1.71%)
PRIMECAP Management 853,900 sh (-1.74%)
Pioneer Investments 31,754 sh (-55.14%)
» More
Q1 2017

NUVA Guru Trades in Q1 2017

Caxton Associates 6,700 sh (New)
Paul Tudor Jones 9,388 sh (New)
Jim Simons 57,188 sh (New)
Steven Cohen 94,800 sh (New)
Pioneer Investments 64,654 sh (+103.61%)
Andreas Halvorsen 1,232,532 sh (+77.16%)
PRIMECAP Management 853,000 sh (-0.11%)
Mario Gabelli 161,555 sh (-0.58%)
Ken Fisher 1,354,648 sh (-3.12%)
Jana Partners 1,201,837 sh (-33.61%)
» More
Q2 2017

NUVA Guru Trades in Q2 2017

Jim Simons 314,888 sh (+450.62%)
Andreas Halvorsen 1,800,463 sh (+46.08%)
Jana Partners 1,690,175 sh (+40.63%)
Paul Tudor Jones 9,816 sh (+4.56%)
Mario Gabelli 161,858 sh (+0.19%)
Pioneer Investments Sold Out
Steven Cohen Sold Out
Caxton Associates Sold Out
PRIMECAP Management 852,000 sh (-0.12%)
Ken Fisher 1,321,423 sh (-2.45%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -2.45%$70.44 - $79.97 $ 53.65-28%1,321,423
Mario Gabelli 2017-06-30 Add 0.19%$70.44 - $79.97 $ 53.65-28%161,858
Ken Fisher 2017-03-31 Reduce -3.12%0.01%$66.16 - $75.83 $ 53.65-26%1,354,648
Mario Gabelli 2017-03-31 Reduce -0.58%$66.16 - $75.83 $ 53.65-26%161,555
Ken Fisher 2016-12-31 Reduce -1.71%$56.71 - $68.38 $ 53.65-17%1,398,259
Mario Gabelli 2016-12-31 Reduce -1.52%$56.71 - $68.38 $ 53.65-17%162,500
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:GMED, NAS:WMGI, NYSE:PEN, NYSE:NVRO, SZSE:002223, OCSE:AMBU B, HKSE:01066, XSWX:TECN, NAS:LIVN, TSE:8086, NAS:INGN, SZSE:300529, OCSE:OSSR, XSWX:YPSN, TSE:6849, TSE:7575, NAS:IART, OSTO:EKTA B, NAS:SPNC, XTER:DRW3 » details
Traded in other countries:NK8.Germany,
Headquarter Location:USA
NuVasive Inc is a medical device company. It develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its product portfolio is focused on applications for spine fusion surgery.

NuVasive is a medical-device company focused on minimally invasive surgical products and integrated solutions for spine surgery. The firm's spine surgery products contribute the majority of revenue. Its key offering is the maximum access surgery minimally disruptive surgical platform, which minimizes soft-tissue disruption and contact with critical nerves and maximizes visualization during spine fusion surgery. NuVasive also develops biologics used to aid in the spinal fusion or bone-healing processes, such as a collagen-based synthetic bone substitute and synthetic bone-graft material. NuVasive generates the majority of its revenue in the United States.

Ratios

vs
industry
vs
history
PE Ratio 86.39
NUVA's PE Ratio is ranked lower than
87% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. NUVA: 86.39 )
Ranked among companies with meaningful PE Ratio only.
NUVA' s PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 81.89 Max: 387.67
Current: 86.39
11.39
387.67
Forward PE Ratio 21.79
NUVA's Forward PE Ratio is ranked higher than
62% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. NUVA: 21.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 86.39
NUVA's PE Ratio without NRI is ranked lower than
87% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. NUVA: 86.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
NUVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.39  Med: 81.89 Max: 387.67
Current: 86.39
11.39
387.67
PB Ratio 3.94
NUVA's PB Ratio is ranked lower than
63% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NUVA: 3.94 )
Ranked among companies with meaningful PB Ratio only.
NUVA' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.77 Max: 10.89
Current: 3.94
0.98
10.89
PS Ratio 2.95
NUVA's PS Ratio is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. NUVA: 2.95 )
Ranked among companies with meaningful PS Ratio only.
NUVA' s PS Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.16 Max: 10.65
Current: 2.95
0.86
10.65
Price-to-Free-Cash-Flow 175.55
NUVA's Price-to-Free-Cash-Flow is ranked lower than
95% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. NUVA: 175.55 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NUVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 55.78 Max: 687.63
Current: 175.55
6.98
687.63
Price-to-Operating-Cash-Flow 24.80
NUVA's Price-to-Operating-Cash-Flow is ranked lower than
62% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. NUVA: 24.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NUVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.77  Med: 19.47 Max: 372.21
Current: 24.8
4.77
372.21
EV-to-EBIT 31.57
NUVA's EV-to-EBIT is ranked lower than
66% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. NUVA: 31.57 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166  Med: 30.8 Max: 559.6
Current: 31.57
-166
559.6
EV-to-EBITDA 14.92
NUVA's EV-to-EBITDA is ranked higher than
55% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. NUVA: 14.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
NUVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -325.2  Med: 17.55 Max: 4339.7
Current: 14.92
-325.2
4339.7
EV-to-Revenue 3.18
NUVA's EV-to-Revenue is ranked higher than
51% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. NUVA: 3.18 )
Ranked among companies with meaningful EV-to-Revenue only.
NUVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 3.45 Max: 10.7
Current: 3.18
1.1
10.7
Shiller PE Ratio 315.18
NUVA's Shiller PE Ratio is ranked lower than
98% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 50.47 vs. NUVA: 315.18 )
Ranked among companies with meaningful Shiller PE Ratio only.
NUVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 299.17  Med: 577.08 Max: 842.75
Current: 315.18
299.17
842.75
Current Ratio 2.40
NUVA's Current Ratio is ranked lower than
54% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. NUVA: 2.40 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s Current Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.2 Max: 15.05
Current: 2.4
1.58
15.05
Quick Ratio 1.44
NUVA's Quick Ratio is ranked lower than
66% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. NUVA: 1.44 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 3.93 Max: 13.9
Current: 1.44
1.14
13.9
Days Inventory 311.02
NUVA's Days Inventory is ranked lower than
85% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. NUVA: 311.02 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s Days Inventory Range Over the Past 10 Years
Min: 266.24  Med: 334.46 Max: 491.78
Current: 311.02
266.24
491.78
Days Sales Outstanding 67.97
NUVA's Days Sales Outstanding is ranked higher than
50% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. NUVA: 67.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.35  Med: 58.06 Max: 75.34
Current: 67.97
52.35
75.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
NUVA's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. NUVA: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NUVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -215.4  Med: -5 Max: -3.8
Current: -3.9
-215.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.29
NUVA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
69% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. NUVA: 3.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NUVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.21  Med: 2.7 Max: 25.15
Current: 3.29
1.21
25.15
Price-to-Median-PS-Value 0.95
NUVA's Price-to-Median-PS-Value is ranked higher than
57% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. NUVA: 0.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NUVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.06 Max: 2.85
Current: 0.95
0.3
2.85
Earnings Yield (Greenblatt) % 3.18
NUVA's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. NUVA: 3.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NUVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.3  Med: 1.2 Max: 6.8
Current: 3.18
-14.3
6.8

More Statistics

Revenue (TTM) (Mil) $1,021.20
EPS (TTM) $ 0.62
Beta1.15
Short Percentage of Float13.25%
52-Week Range $49.25 - 81.68
Shares Outstanding (Mil)50.80

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,061 1,145 1,242 1,316
EPS ($) 2.00 2.40 2.85 3.32
EPS without NRI ($) 2.00 2.40 2.85 3.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.30%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}